Glycotope picks Crown Bioscience to work together on immuno-oncology drug discovery pipeline

Glycotope has chosen Crown Bioscience to work together on immuno-oncology drug discovery pipeline, the subsidiary of Crown Bioscience Internation said Wednesday. 

It said in its press release that it will engraft cell line-derived cancer models as well as PDX models selected by Glycotope into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Glycotope’s innovative immuno-oncology drug discovery pipeline.

Anika Jäkel, Director of Glycotope’s Preclinical Pharmacology & Cancer Immunology group, said Glycotope has picked Bioscience as its partner for the value of CrownBio’s extensive PDX and CDX collection and their expertise in implementing innovative humanization strategies.

Laurie Heilmann, CrownBio’s Chief Business Officer, said: “Our unique capabilities will enable Glycotope to continue providing new and improved therapies for the treatment of cancer.”